anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, surgery. SUBSTANCE: in postoperational period one should introduce an ozonized physiological solution through nasointestinal probe into small intestinal lumen for 7 d at 4-7 mg/l concentration and 200 ml volume. Simultaneously, since the 1st d of postoperational period one should carry out a rectal insufflation of ozone-oxygen mixture at 30 mg/l concentration and 300 ml volume at exposure being not less than 15 min. There are 7 insufflations at 3-4-d-long interval. The method in question enables to inactivate microorganisms due to bactericidal effect of ozone. EFFECT: higher efficiency of therapy. 7 dwg
Type 2 Diabetes and cardiovascular disease are closely linked. A common abnormality in both conditions is insulin resistance. The primary cause of insulin resistance in not known. A significant question is what dietary components contribute to the development of insulin resistance. Based on epidemiologic data, it seems that the type of dietary fat is a significant contributor to the development of insulin resistance. However, some researchers argue that the main determinant is total amount of fat, not the composition.

This study is intended to determine if the main types of fat (saturated, monounsaturated and polyunsaturated) ingested over a short time can cause insulin resistance in lean, healthy people. It has been demonstrated that 6 hours of intravenous fat infused into lean, healthy subjects can result in insulin resistance, as well as blood pressure elevation and endothelial dysfunction. Whether this is so with oral fat is not known. The question is important because there is debate about whether the type of fat is as important as the quantity of fat in a person's daily diet. Settling this debate will enhance the ability of health care personnel to determine the optimal dietary recommendations.

This study will make use of a high fat diet consisting of vegetable oils high in the 3 main fatty acids in plasma (palmitate, oleate and linoleate). Because large fat loads can cause intestinal discomfort, a feeding tube will be used to bypass the stomach. The 3 oils will be assigned randomly following a base line study with saline 2 weeks prior to the intervention. Our primary endpoint is insulin resistance, which will be measured by a euglycemic, hyperinsulinemic clamp. Secondary measures will include changes in blood pressure and in vascular reactivity as measured by ultrasound after brief occlusion of a forearm vessel. The changes will be compared to baseline and to the other 2 groups.
PURPOSE: To obtain a solid bath agent having an excellent solubility, hardly broken, easily prepared and provided with a recessed part. CONSTITUTION: The bath agent blended with 5-80wt.% carbonate salt and 10-80wt.% organic acid for imparting a foaming property, comprises forming a recessed part in the middle of right surface side thereof. The depth of the recessed part is 50-80% thickness of the bath agent and the volume of the recessed part is 1-3% of the volume of the agent, its planer shape is almost a square having 40-50mm sides or a circle having 40-50mm diameter, its thickness is 10-20mm, the diameter of the opening edge part of the recessed part is 20-25mm) and the diameter at the middle part in the depth direction is 5-15mm, and the shape of the inside wall is the convex curved surface of an approximately reversed truncated cone shape.  As the bottom of the recessed part becomes a perforated hole during the dissolution in the warm bath water and the agent is dissolved from the outer peripheral surface and the wall surface of the perforated hole, an excellent solubility is manifested. Just putting the agent into the warm bath water and taking a bath after its dissolution is satisfactory, and it is preferable that the warm bath water becomes pH4-6. 5 at that time.
The present invention discloses medicated liquor for curing rheumatism and traumatic injuries, which relates to a medicine preparation. The present invention aims to add a medicine for curing rheumatism and traumatic injuries. The medicated liquor at least comprises two kinds of traditional Chinese medicines of notoginseng and sanguisorba root. The more dosage of the notoginseng sanguisorba root, the shorter liquor immersion time is needed. Usually and preferably, 120g of sanguisorba root and 40g of notoginseng are added to every 1000 ml of liquor. The medicated liquor of the present invention can be used for treating diseases such as traumatic injuries, various kinds of fracture, rheumarthritis, rheumatoid arthritis, nerve numbness, myotenositis, tendon injuries, the relapse of old tendon injuries, chronic gastroenteritis, hemoptysis, hematemesis, hemafecia, hematuria, hemorrhoids bleeding, dysfunctional uterine bleeding, dysentery, scapulohumeral periarthritis, etc.
No intervention was applied to the control group except for the routine nursing care. The data collection process in the control group was conducted in parallel with the acupressure and placebo groups. Pain score of women was recorded prior to intervention in the acupressure and placebo groups. The duration of intervention in the acupressure and placebo groups was 12 minutes and the measurements were repeated 15 minutes after the intervention. The average duration between the first and the second measurements is 30 minutes in the acupressure and placebo groups. In parallel with the acupressure and placebo groups, the current pain score of the women was recorded at the postpartum second hour (Time 1) and 30 minutes later (Time 2), and at the fourth hour (Time 3) and 30 minutes later (Time 4). Additionally, the analgesic substance and its amount applied during the application were recorded by the first researcher.
The present invention provides compounds of the formula below: where A, X and R1-R6 are as described herein, a pharmaceutical salt thereof, and a pharmaceutical composition containing this compound; methods of treating pain associated with osteoarthritis using one of the compounds or a pharmaceutically acceptable salt thereof, and processes for preparing the compounds. The present invention provides compounds of the formula below: where A, X and R1-R6 are as described herein, a pharmaceutical salt thereof, and a pharmaceutical composition containing this compound; methods of treating pain associated with osteoarthritis using one of the compounds or a pharmaceutically acceptable salt thereof, and processes for preparing the compounds. ABSTRACT An electrical contact including a male termination end configured to be removably inserted into a female termination end of a mating contact. The male termination end having a slot between two beam sections. The slot is formed by a section of the male termination end having had material removed between the two beam sections. The two beam sections are outwardly deformed in opposite directions. The two beam sections are substantially parallel to each other along a majority of length of the male termination end.
It has been discovered that the combination of resveratrol, dichloroacetate and niacin has a synergistic effect when used to treat hemorrhagic injury. One embodiment provides a pharmaceutical composition containing an effective amount of resveratrol, dichloroacetate and niacin to improve cardiac function following severe hemorrhage versus a control that did not received the combination treatment. Resveratrol, dichloroacetate and niacin can each independently be present in the pharmaceutical composition in an amount from 2 mg/kg body weight to 10 mg/kg body weight. In one embodiment, resveratrol, dichloroacetate and niacin are each present in an amount of 2 mg/kg body weight. The pharmaceutical formulation can be formulated as one unit dose containing all three compounds. In other embodiments, each compound is formulated as a separate pharmaceutical composition that can be administered to a subject in need thereof simultaneously, in alternation, or in combination.
Elevations of aminotransferases may occur in patients receiving VELSIPITY. In UC-1, elevations of alanine transaminase (ALT) greater than 3-fold the upper limit of normal (ULN) occurred in 4.5% of subjects who received VELSIPITY and 2.1% of subjects who received placebo. In UC-2 and UC-3, elevations of ALT greater than 3-fold the ULN occurred in 2.5% of subjects who received VELSIPITY and 0.5% of subjects who received placebo. 

Obtain transaminase and bilirubin levels, if not recently available (i.e., within last 6 months), before initiation of VELSIPITY.

Obtain transaminases and bilirubin in patients who develop symptoms suggestive of hepatic dysfunction, such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine. Discontinue VELSIPITY if significant liver injury is confirmed.
Thoracotomy is considered the most painful of surgical procedures and providing effective analgesia is the onus for all anesthetists. Ineffective pain relief impedes deep breathing, coughing, and remobilization culminating in atelectasis and pneumonia.The erector spinae plane (ESP) block is a newly-described technique for treating thoracic pain, and has several advantages that make it an attractive alternative to these more invasive procedures.Ultrasound guided erector spinae (ESP) block is a regional anesthesia technique, recently described by (Forero; et al.) for use in thoracic neuropathic pain. ESP block is reported to lead to analgesic effect on somatic and visceral pain by effecting the ventral rami and rami communicantes that include sympathetic nerve fibers, as LA spreads through the paravertebral space . When performed bilaterally it has been reported to be as effective as thoracic epidural analgesia.ESP block leads to effective postoperative analgesia when performed at T 4-5 level for breast and thoracic surgery. The ESP block , will be performed as follow:The patient will be placed in a sitting position and the ultrasound probe will be placed in a longitudinal orientation 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae . the needle will be inserted in a cephalad-to-caudad direction until the tip lay deep to erector spinae muscles, as evidenced by visible linear spread of fluid beneath muscle upon injection . A total of 20 mL of 0.25% bupivacaine will be injected here.
The invention relates to a Chinese traditional medicine facial mask prescription for treating melasma, a preparation method thereof and a usage method. The Chinese traditional medicine prescription is suitable for melasma women. The prescription comprises the following components by weight: 15g of radix bupleuri, 15g of red flower, 15g of peach kernels, 15g of white paeony roots, 15g of fructus ligustri lucidi, 15g of fructus aurantii, 15g of luffa, 15g of frankincense, 15g of zedoary turmeric oil and 15g of pearl powder. The preparation method of the Chinese traditional medicine prescription comprises the following steps: weighing the above Chinese traditional medicines excluding the pearl powder in the prescription by weight, crushing and grinding the Chinese traditional medicines excluding the pearl powder into 60 meshes of powder, grinding the powder into 100 meshes of powder after the pearl powder is added, fully agitating and homogenizing the powder; and the powder is packed according to 30g/package. The usage method includes the steps of diluting 30g of the powder with boiled water at the temperature of 90-100 DEG C, adding the egg white of an egg, two vitamin E pills and 1/3 of a mixture of a soup spoon of honey and homogenizing till the temperature of the medicine does not burn skin, uniformly applying the medicine at the affected part, applying a plastic film on the medicine, keeping 30 minutes, removing the medicine and cleaning the face. A serious patient applies once a day, and a mild patient applies once every other day.
Participants will receive at least 4 doses of rituximab 1400 mg SC once a month during the Induction period, and at least 6 doses of rituximab 1400 mg SC once every two months during the Maintenance period, in addition to standard chemotherapy. Standard chemotherapy regimen included cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP); or cyclophosphamide, vincristine and prednisone (CVP); or bendamustine as per standard local practice.
BACKGROUND: High HIV viral loads (VL) are associated with increased morbidity, mortality, and on-going transmission. HIV controllers maintain low VLs in the absence of antiretroviral therapy (ART). We previously used a massively multiplexed antibody profiling assay (VirScan) to compare antibody profiles in HIV controllers and persons living with HIV (PWH) who were virally suppressed on ART. In this report, we used VirScan to evaluate whether antibody reactivity to specific HIV targets and broad reactivity across the HIV genome was associated with VL and controller status 1-2 years after infection.
METHODS: Samples were obtained from participants who acquired HIV infection in a community-randomized trial in Africa that evaluated an integrated strategy for HIV prevention (HPTN 071 PopART). Controller status was determined using VL and antiretroviral (ARV) drug data obtained at the seroconversion visit and 1 year later. Viremic controllers had VLs <2,000 copies/mL at both visits; non-controllers had VLs >2,000 copies/mL at both visits. Both groups had no ARV drugs detected at either visit. VirScan testing was performed at the second HIV-positive visit (1-2 years after HIV infection).
RESULTS: The study cohort included 13 viremic controllers and 64 non-controllers. We identified ten clusters of homologous peptides that had high levels of antibody reactivity (three in gag, three in env, two in integrase, one in protease, and one in vpu). Reactivity to 43 peptides (eight unique epitopes) in six of these clusters was associated with lower VL; reactivity to six of the eight epitopes was associated with HIV controller status. Higher aggregate antibody reactivity across the eight epitopes (more epitopes targeted, higher mean reactivity across all epitopes) and across the HIV genome was also associated with lower VL and controller status.
CONCLUSIONS: We identified HIV antibody targets associated with lower VL and HIV controller status 1-2 years after infection. Robust aggregate responses to these targets and broad antibody reactivity across the HIV genome were also associated with lower VL and controller status. These findings provide novel insights into the relationship between humoral immunity and viral containment that could help inform the design of antibody-based approaches for reducing HIV VL.
Participants will be invited to read about and practice a variety of mindful eating-related strategies over the course of 10 weeks based on Dr. Michelle May \& Dr. Kari Anderson's self-help book entitled, "Eat What You Love, Love What You Eat for Binge Eating". Participants will also be asked to complete a weekly electronic log describing their experiences with the weekly mindfulness-based practices.
The invention provides a capsule composition for treating gastric ulcer and duodenal ulcer and a preparation method of the capsule composition, aiming at overcoming the shortage of the prior art. The capsule composition comprises the following raw materials in parts by weight: 18 to 22g of liquorice, 18 to 22g of pueraria flower, 18 to 22g of radix puerariae, 18 to 22g of fructus amomi, 18 to 22g of galangal, and 13 to 17g of radix paeoniae alba. The capsule composition is in a form of a capsule finally. The preparation method comprises the following steps of purifying at three times; concentrating; preparing dry powder; granulating and filling into a capsule; sterilizing; and warehousing. The capsule composition has the effects of strengthening spleen and invigorating Qi, strengthening mid-energy and harmonizing stomach, regulating vital energy and eliminating distension, relieving for stopping pain, and clearing heat and removing toxicity. The capsule composition is stable in quality, small in dose for taking orally, convenient to take, fast to absorb, high in bioavailability, and simple in production process.
Group 1 will receive Autogenic inhibition with conventional treatment. Autogenic inhibition will be applied to the muscles of the anterior tibial compartment, including Tibialis anterior, extensor hallucis longus, extensor digitorum longus (Perform Dorsi-Flexion), Lateral Tibial Muscles (Peronei), and posterior tibial muscles including, gastrocnemius, soleus and plantaris (Perform Plantarflexion).
As with all therapeutic proteins, there is the potential for immunogenicity with LEUKINE. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, duration of treatment, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to sargramostim in the studies described below with the incidence of antibodies in other studies or other products may be misleading.

In 214 patients with a variety of underlying diseases, neutralizing anti-sargramostim antibodies were detected in 5 patients (2.3%) after receiving LEUKINE by continuous IV infusion (3 patients) or SC injection (2 patients) for 28 to 84 days in multiple courses (as assessed by GM-CSF dependent human cell-line proliferation assay). All 5 patients had impaired hematopoiesis before the administration of LEUKINE, and consequently the effect of the development of anti-sargramostim antibodies on normal hematopoiesis could not be assessed. 

Antibody studies of 75 patients with Crohn's disease (a disease for which LEUKINE is not indicated), with normal hematopoiesis and no other immunosuppressive drugs, receiving LEUKINE daily for 8 weeks by SC injection, showed 1 patient (1.3%) with detectable neutralizing anti-sargramostim antibodies (as assessed by GM-CSF dependent human cell-line proliferation assay). 

In an experimental use trial where LEUKINE was given for an extended period, 53 patients with melanoma in complete remission (a disease for which LEUKINE is not indicated) received adjuvant therapy with LEUKINE 125 mcg/m2 once daily (maximum dose 250 mcg) from day 1 to 14 every 28 days for 1 year. Serum samples from patients assessed at day 0, 2 weeks, 1 month, and 5 and/or 12 months were tested retrospectively for the presence of anti-sargramostim antibodies. Of 43 evaluable patients (having at least 3 timepoint samples post treatment), 42 (97.7%) developed anti-sargramostim binding antibody as assessed by ELISA and confirmed using an immunoprecipitation assay. Of these 42 patients, 41 had sufficient sample and were further tested: 34 patients (82.9%) developed anti-sargramostim neutralizing antibodies (as determined by a cell based luciferase reporter gene neutralizing antibody assay); 17 (50%) of these patients did not have a sustained pharmacodynamic effect of LEUKINE by day 155 as assessed by WBC counts. This study provided limited assessment of the impact of antibody formation on the safety and efficacy of LEUKINE.

Serious allergic and anaphylactoid reactions have been reported with LEUKINE, but the rate of occurrence of antibodies in such patients has not been assessed.
Patients receive oral nitazoxanide daily for 14 days, after which those with complete clinical and parasitologic response discontinue treatment. Non-responders and partial responders may continue therapy for an additional 14 days at the discretion of the physician. Non-responders who show signs of improvement or who have partial response after 28 days and those who relapse following complete response may continue therapy for an additional month, up to 60 days total. \[AS PER AMENDMENT 10/30/96: Patients receive a daily treatment for 4 weeks, with subsequent dose escalation in the absence of drug-related toxicity. Patients who exhibit complete response after 2 months may continue at a maintenance dose. Patients enrolled after October 15, 1996 are randomized to 1 of 2 doses, with subsequent escalations made in the absence of toxicity. Complete responders may continue therapy at a maintenance dose and duration determined by the investigator. Non-responders after 6 months of therapy have treatment discontinued.\] \[AS PER AMENDMENT 8/5/97: All patients are evaluated at Weeks 1, 2, 4, and monthly thereafter.\] \[AS PER AMENDMENT 8/17/99: New patients start therapy on a different dosage of nitazoxanide. Those who do not respond after 4 weeks of therapy will escalate to a higher dosage. Patients who show a complete response at 2 consecutive visits (2 weeks apart) discontinue nitazoxanide therapy and go to follow-up.\] \[AS PER AMENDMENT 2/3/00: The Week 1 clinical evaluation is deleted from the study procedures.\]
Adipose tissue is a multifunctional organ that regulates many physiological processes such as energy homeostasis, nutrition, the regulation of insulin sensitivity, body temperature, and immune response. In this review, we highlight the relevance of the different mediators that control adipose tissue activity through a systematic review of the main players present in white and brown adipose tissues. Among them, inflammatory mediators secreted by the adipose tissue, such as classical adipokines and more recent ones, elements of the immune system infiltrated into the adipose tissue (certain cell types and interleukins), as well as the role of intestinal microbiota and derived metabolites, have been reviewed. Furthermore, anti-obesity mediators that promote the activation of beige adipose tissue, e.g., myokines, thyroid hormones, amino acids, and both long and micro RNAs, are exhaustively examined. Finally, we also analyze therapeutic strategies based on those mediators that have been described to date. In conclusion, novel regulators of obesity, such as microRNAs or microbiota, are being characterized and are promising tools to treat obesity in the future.
Retinal degenerative diseases affect the delicate layer of retina tissue that lines the inside back of the eye leading to gradual vision loss. The use of opioid anatgonists for the preparation of a medicament for the selective blocking of the body's opioid receptors sites is a method of treating this human suffering by daily administration to the patient of from about 0.5 to about 10 mg of drugs such as naltrexone, naloxone or nalmefene. They act primarily by normalizing derangements in the human complement system that may occur in the disease etiology. Therapeutical approach for macular degeneration and retinitis pigmentosa is primarily intended. Oral, parenteral uses as well as topical applications may all be considered. They may be administered in one or divided doses daily for the best receptor blocking activity, preferably in the evening hours. Low Dose Naltrexone suitable for oral administration is most preferred regimen at about 4.5 mg/day.
Cystic fibrosis patients with active lung disease will undergo a high resolution PET-CT.PET/CT scans (GE ST Discovery PET/CT scanner) will be performed 60 to 90 minutes after injection of 5 MBq/kg of FDG. PET/CT will be repeated at the end of the treatment and compared with the results of the initial scan. PET and CT will be interpreted by a certified nuclear medicine physician and by a certified radiologist, respectively, blinded to clinical data, using the PET severity score (PSS), based on the number and the intensity of FDG uptake of lung foci. Intensity of uptake will be determined by calculating the mean value for the maximum standardized uptake values (MSUV) of all foci.

(SUV = Activity concentration in ROI (region of interest) divided by injected dose / patient body weight). SUV will be measured in normal lungs to receive the normal baseline control for the calculations. The correlation with clinical data (FEV1% predicted) and sputum bacteriology will then be performed. Inflammation status will also be followed by cytokine analysis.